In this guide
What is anastrozole?
Anastrozole is a prescription tablet that lowers estrogen by blocking the enzyme that makes it. It is approved only to treat breast cancer in women after menopause. Men meet it in two very different ways: added to testosterone therapy to bring down a high estradiol result, or on its own to raise their own testosterone. [1], [2], [3]
It belongs to a group called aromatase inhibitors. Aromatase is the enzyme that converts testosterone into estradiol, the main form of estrogen. It is found in fat tissue, the testicles, the brain and bone. Anastrozole sits in that enzyme and stops it working for as long as the drug is present, so less estradiol is made. It is not a steroid or a hormone; the US label calls it a selective non-steroidal aromatase inhibitor. [4], [1]
Two facts surprise many men on TRT. Men need estradiol for strong bones, body-fat control and sex drive, so lower is not automatically better. And no label or major guideline gives a dose for adding anastrozole to TRT; the US Veterans Affairs (VA) recommendations do not generally recommend it. [5], [6], [7]
It was first approved in the United States on December 27, 1995, as Arimidex. [8]
| Product | Where | Form and strength | Status (checked September 2026) |
|---|---|---|---|
| Arimidex and generic anastrozole | United States | 1 mg film-coated tablet | Prescription; Arimidex now sold by ANI Pharmaceuticals |
| Arimidex and generic anastrozole | United Kingdom | 1 mg film-coated tablet | Prescription-only medicine |
| Arimidex and 17 generics | Canada | 1 mg tablet | 18 products listed as marketed |
| Anastrozole 1 mg | Australia | 1 mg tablet | Prescription-only (Schedule 4); subsidized only for breast cancer |
[9], [10], [11], [12], [13], [14]
1 mg is the only strength sold anywhere covered here, and there is no licensed liquid. The tablets are not scored for splitting (see tablets). [1], [10]

Typical Anastrozole Protocols
| Source | Amount each time | How often | Weekly total | Course and adjustment | Source type |
|---|---|---|---|---|---|
| US label · breast cancer in women after menopause (the only labeled use) | 1 mg | Once daily | 7 mg | 5 years after surgery in the pivotal trial; no dose adjustment | Label |
| UK label · breast cancer treatment and prevention in women after menopause | 1 mg | Once daily | 7 mg | 5 years; no dose adjustment | Label Canada's monograph and the harmonized EU text give the same dose; no label anywhere gives a dose for men |
| American Urological Association (AUA) 2018 · instead of testosterone, for men who want to keep fertility | 0.05–1 mg (as printed) | Every 1–3 days | Not stated | Adjust by estradiol; stop if estradiol stays high; first blood test no sooner than 4 weeks; avoid long-term use | Guideline Marked not FDA-approved in males. The printed lower figure may be a misprint for 0.5 mg; it is shown exactly as the guideline prints it |
| Brazilian societies 2026 (endocrinology, urology, sexual medicine) · instead of testosterone (fertility, obesity, prolactinoma) | 0.5–1 mg | Daily or every other day | 1.75–7 mg | Continuous while needed and tolerated; not with osteoporosis or severe liver disease | Guideline |
| Trial · older men with low testosterone, instead of TRT | 1 mg | Once daily | 7 mg | 12 weeks; fixed dose | Human trial |
| Same trial · lower-frequency arm | 1 mg | Twice a week | 2 mg | 12 weeks; fixed dose | Human trial |
| Trial · men 60 and older with low or low-normal testosterone, instead of TRT | 1 mg | Once daily | 7 mg | 1 year; fixed dose | Human trial |
| Trial · infertile men with low testosterone, compared with clomiphene | 1 mg | Once daily | 7 mg | 12 weeks; fixed dose | Human trial |
| Study · subfertile men with low testosterone and overweight, no comparison group | 1 mg | Once daily | 7 mg | About 5 months | Human report |
| Trial · healthy older men given testosterone enanthate 100 mg weekly (research design) | 1 mg | Once daily, alongside the testosterone | 7 mg | 6 weeks; fixed dose | Human trial Built to block estradiol completely for research, not as a treatment schedule |
| Study · men on testosterone pellets | 1 mg | Once daily, by mouth | 7 mg | Between pellet insertions | Human report |
Every label, trial and study uses the 1 mg tablet, most often once a day. The two guideline ranges are for anastrozole used instead of testosterone, not added to it. No label or major guideline gives a dose for adding anastrozole to TRT; the only published on-TRT clinic schedule is 0.5 mg three times a week (below). [1], [15], [2], [3]
- Titration Adjusting the dose
- The labels do not adjust the dose. When anastrozole is used instead of testosterone, the AUA adjusts it by estradiol to keep estradiol in range, stops it if estradiol stays high, and checks blood no sooner than 4 weeks after starting. The one published on-TRT clinic series changed the dose or frequency to keep estradiol between 20 and 40 pg/mL (about 73–147 pmol/L). No guideline sets an estradiol target for men on TRT. [15], [3]
- Breaks and courses
- Anastrozole is not a cycle and has no planned breaks. The AUA says aromatase inhibitors should in general not be used for long periods because of bone loss, while the Brazilian statement describes continuous use while it is needed and tolerated, with long-term follow-up. Stopping is covered below. [15], [2]
Read the units. Anastrozole comes only as a 1 mg tablet, so any other dose means taking it less often or cutting tablets. The tablets are not scored, and no label gives splitting instructions, so a "quarter tablet" is not a measured 0.25 mg. No syringe arithmetic applies. Compare weekly totals: 1 mg twice a week is 2 mg a week; 1 mg daily is 7 mg. [1], [10], [11]
These are labeled, guideline and study doses; no label or major guideline gives a dose for adding anastrozole to TRT, and prescribers who use it adjust by estradiol and symptoms. These guides are for men; testosterone therapy for women is covered in testosterone therapy for women.
Cautions for every schedule above. Lowering estradiol lowers bone density in men, and the labels advise considering bone and cholesterol checks. The Brazilian statement rules it out with osteoporosis, marked bone thinning (osteopenia) or severe liver disease. The labels say it should not be taken with tamoxifen or estrogen-containing medicines, and taking it alongside TRT does not protect sperm production (fertility). For breast symptoms on TRT, the AUA considers lowering the testosterone dose first (where sources differ). [22], [1], [11], [2], [23], [24]
Where these numbers come from
The label rows come from the current US Arimidex label (printed revision December 2025; DailyMed updated March 2, 2026) and the UK Arimidex SmPC (revised August 12, 2026). The Canadian monograph (revised December 23, 2024) and the 2011 harmonized EU product information give the same 1 mg daily dose for women after menopause. Weekly totals are simple multiplications; the labels do not state them. [1], [11], [25], [26]
The guideline rows come from Table 6 of the AUA testosterone deficiency guideline (2018), which lists anastrozole "0.05 - 1 mg every 1-3 days" among alternatives to testosterone and marks it not FDA-approved in males, and from the 2026 joint position statement of three Brazilian societies (endocrinology, urology and sexual medicine), which gives "0.5–1 mg daily or on alternate days". The Brazilian weekly total runs from 0.5 mg every other day to 1 mg daily. [15], [2]
The trial and study rows each come from one published study: Leder 2004 (both arms), Burnett-Bowie 2009, Helo 2015, Shah 2021, Cherrier 2005 and Mechlin 2014. Other trials and studies used the same 1 mg daily schedule, including Dias 2016 (12 months, compared with testosterone gel) and Pelit 2025 (3 months before sperm-retrieval surgery in Klinefelter syndrome). The on-TRT clinic row below comes from Punjani 2021, read in full text. [16], [17], [18], [19], [20], [21], [6], [27], [3]
Not used for any row: the 10 mg daily dose of a one-week physiology study (a research dose), the 0.5 and 1 mg doses of a 10-day dose-finding study in young males, a median of 3 mg a week from a fertility cohort (a median, not a schedule), trials whose anastrozole dose is not in the abstract (the epilepsy trial of anastrozole with testosterone and a clomiphene combination series), "micro-doses" of 0.25 mg or less, dosing on injection day, as-needed dosing, liquid or compounded anastrozole (no primary source), and any use with steroid cycles or as "post-cycle therapy". [28], [29], [30], [31], [32]
What do clinic protocol sources use on TRT?
| Source | Amount each time | How often | Weekly total | Who got it and how it was adjusted | Source type |
|---|---|---|---|---|---|
| US sexual-medicine clinic series (2021) · men on testosterone therapy | 0.5 mg | Three times a week | 1.5 mg | Estradiol above 60 pg/mL (about 220 pmol/L), or 40–60 pg/mL with breast or nipple tenderness; dose or frequency changed to keep estradiol at 20–40 pg/mL | Clinic protocol source 44 of 1,708 men (2.6%) in this practice met these criteria |
This is the only complete, published on-TRT schedule found for this guide (the paper's "testosterone therapy" group also included some men on clomiphene). Median estradiol fell from 65 to 22 pg/mL (about 239 to 81 pmol/L) while testosterone did not change (616 vs 596 ng/dL, about 21.4 vs 20.7 nmol/L). Symptoms, bone and side effects were not reported. [3]
Elsewhere, practice varies widely: in a 2020 survey of 489 sexual-medicine clinicians, anastrozole starting doses ranged from 1 mg a week to 1 mg a day, a sevenfold spread of habits rather than a schedule. [33]
What is anastrozole commonly used for in men?
Its only labeled use is breast cancer in women after menopause; the UK label adds breast cancer prevention in women at higher risk. Everything below is off-label use in men, and the evidence behind each use differs a great deal. [1], [11]
- Lowering estradiol on TRT. The most common reason men on testosterone hear about it. Some clinics prescribe it for a lab number, some for symptoms, some for everyone. The evidence for any benefit here is thin.
- Raising testosterone instead of TRT. Blocking estradiol makes the brain send more signal to the testicles, so a man whose testicles work makes more testosterone. Testosterone rises reliably; how men feel does not.
- Fertility. For men with low testosterone who want children, several guidelines list aromatase inhibitors as an off-label alternative to testosterone, which shuts sperm production down.
- Breast growth (gynecomastia). Anastrozole has done poorly in the trials that tested it; tamoxifen did better.
- Specialist uses. Male breast cancer (always with a second drug), some pituitary tumors and rare genetic conditions.

Does anastrozole help men on TRT?
It lowers estradiol, but no trial has shown that adding it to TRT makes men feel or function better. On full-dose TRT the brain's signal to the testicles is largely switched off, so in the one clinic series testosterone did not change when anastrozole lowered estradiol; with waning pellets, adding it kept testosterone up longer. [3], [21]
- The only randomized trial found in men treated for low testosterone gave 40 men with epilepsy, low testosterone and low sex drive testosterone injections plus anastrozole or a placebo for 3 months. Sexual function returned to normal in 72.2% vs 47.4%, a difference that was not statistically significant. [31]
- A research trial in 60 healthy older men gave testosterone enanthate 100 mg weekly with or without anastrozole 1 mg daily for 6 weeks. Testosterone alone raised estradiol by 81%; adding anastrozole cut it by 50%. Verbal memory improved only in the men whose estradiol rose. [20]
- In men on testosterone pellets, adding 1 mg daily kept estradiol lower and made pellets last longer (about 198 vs 128 days), in a records review with no bone or symptom outcomes. [21]
- Estradiol and sex drive. In the Testosterone Trials of older men, larger rises in estradiol, as well as testosterone, went with larger gains in sexual desire and activity. When researchers lowered men's hormones on purpose, missing estradiol mainly caused fat gain, and both hormones contributed to sexual function. The International Consultation on Sexual Medicine suggests not using aromatase inhibitors to treat low desire. [36], [5], [37]
How often is estradiol high on TRT? In records from one US men's clinic chain that treated about half of its men with injections, 7,215 of 34,016 men (20.2%) had estradiol at or above 42.6 pg/mL (about 156 pmol/L), measured by a standard immunoassay; the figure mixes men who were screened and men who were treated. High estradiol was not linked to low libido in that data, and the clinic prescribed estrogen-blocking drugs regardless of the level. [38]
Can anastrozole raise testosterone instead of TRT?
Yes, in men whose testicles work, but the trials found no clear benefit from the higher number: no better quality of life or erections at 12 weeks, and no change in body composition or strength after a year. By lowering estradiol, anastrozole lets the pituitary send more LH, and working testicles make more testosterone. [28], [16]
- In 37 men aged 62 to 74, 12 weeks of 1 mg daily raised total testosterone from 343 to 572 ng/dL (about 12 to 20 nmol/L); 1 mg twice a week raised it from 397 to 520 ng/dL (about 14 to 18 nmol/L). Estradiol fell from about 26 to 17 pg/mL in both groups. Quality of life, erections, urinary symptoms and hematocrit did not change. [16]
- In 88 men aged 60 and older, a year of 1 mg daily raised testosterone from 11.2 to 18.2 nmol/L (about 323 to 525 ng/dL) at 3 months, but body composition and strength did not change. In the same trial's bone study, spine bone density fell (bone). [17], [22]
- In 43 men aged 65 to 82 given testosterone gel, anastrozole or placebo for 12 months, both raised testosterone above 500 ng/dL (about 17 nmol/L), but only the gel improved spine bone density and fast walking speed; lean mass rose only with anastrozole (about 1.2–1.5 kg). [6]
- Related drugs tell the same story. An investigational aromatase inhibitor normalized testosterone in 271 men with obesity over 24 weeks without improving sexual symptoms or body composition, and letrozole raised testosterone from 8.6 to 21.5 nmol/L (about 248 to 620 ng/dL) in 42 men with obesity with no physical or psychological benefit. [39], [40]
It only works when the brain-to-testicle chain is intact; the European urology guideline says these drugs cannot work in primary hypogonadism (failing testicles) or when the pituitary is damaged. In a head-to-head trial of 26 infertile men with low testosterone, clomiphene 25 mg a day raised testosterone more than anastrozole 1 mg a day over 12 weeks; estradiol rose on clomiphene and fell on anastrozole, and neither improved semen or how men felt. [41], [18]
Does anastrozole help fertility?
For some men with low testosterone and low sperm counts, it improves hormones and sperm numbers, but the studies are small and mostly uncontrolled, and it does nothing for sperm while taking TRT. [42], [24]
Guidelines give it a limited, off-label place:
- The US male infertility guideline from the AUA and the American Society for Reproductive Medicine (AUA/ASRM) allows aromatase inhibitors, hCG (human chorionic gonadotropin, an LH-like hormone injection) or SERMs for infertile men with low testosterone (a conditional recommendation on weaker evidence), and notes an aromatase inhibitor may be considered when estradiol is also high. [24]
- The AUA, Canadian and British guidelines and the 2026 Brazilian statement list aromatase inhibitors among alternatives to testosterone for men who want to keep fertility. [15], [43], [44], [2]
- The European urology guideline says not to treat unexplained infertility routinely with aromatase inhibitors. [45]
What the studies found:
- Sperm counts rose in selected men. In 25 men with low counts, sperm concentration rose from 5.5 to 15.6 million per mL on 1 mg daily; in 30 men with overweight, from 7.8 to 14.2 million per mL, and 14 couples became pregnant, 10 of them through in vitro fertilization (IVF). Neither study had a control group. [46], [19]
- Men with no sperm rarely respond. In one series, 18 of 21 men with low counts improved but none with azoospermia did, and a 2023 study of 90 men (median dose 3 mg a week) found 41 moved up a sperm-count category, 11 moved down and 26 reached normal counts, with the best results in men who had some sperm and a high testosterone-to-LH ratio. [47], [30]
- Reviews are cautious. A 2020 review of 8 studies (only two small placebo-controlled trials, neither of anastrozole) called for larger placebo-controlled trials; a 2022 meta-analysis of 10 studies found no advantage over SERMs or hCG; a 2024 analysis of 14 randomized trials found insufficient evidence for routine use. [42], [48], [49]
Taken with TRT, it does not protect sperm. The AUA/ASRM guideline says men who want children now or later should not be prescribed testosterone, and calls the evidence for adding other medicines to testosterone too limited to recommend. See TRT and fertility. [24]
Does anastrozole help gynecomastia (breast growth)?
It has done poorly in the trials that tested it. In a double-blind trial of 114 men taking the prostate cancer drug bicalutamide, breast growth developed in 73% on placebo, 51% on anastrozole 1 mg daily and 10% on tamoxifen 20 mg daily. A second report from the same program found that tamoxifen, but not anastrozole, significantly reduced breast growth and pain, whether used to prevent it or to treat it. In 80 boys with breast growth during puberty, 6 months of 1 mg daily worked no better than placebo (38.5% vs 31.4% responded). [34], [50], [51]
On TRT, the only published evidence is a case report of two men. The AUA watches first, then lowers the testosterone dose if levels are upper-normal, or considers an aromatase inhibitor if they are low or normal. The European Academy of Andrology says drug treatment of breast growth is not justified in general, and the Brazilian statement names tamoxifen for breast growth on TRT. See the tamoxifen guide. [52], [15], [53], [2]
What specialist uses does anastrozole have in men?
- Male breast cancer. Guidelines prefer tamoxifen. When an aromatase inhibitor is used, it is paired with a drug that shuts down the pituitary signal (a GnRH agonist); on its own, an aromatase inhibitor raises LH and testosterone in men. [54], [35], [28]
- Prolactin-secreting pituitary tumors (9 reported patients) and Klinefelter syndrome before sperm-retrieval surgery (sperm found in 10 of 22 men after anastrozole vs 4 of 21 after an hCG-type drug, not statistically significant). [55], [27]
- Boys with growth hormone deficiency. The trial authors reported a gain in predicted adult height, but the UK regulator's reading of the same 52-boy trial found no significant height benefit and more fractures, and the UK label says not to use it this way. [56], [11]
It also appears in forums about recovering after steroid cycles; the UK Society for Endocrinology calls the evidence for any such drug "limited and of low quality", and notes most men's hormones recover within about 12 months of stopping. [57]
How quickly does anastrozole work?
Estradiol falls within a day. In women, 1 mg cut estradiol by about 70% within 24 hours. In young males, 0.5 mg and 1 mg daily each cut it by about 50% over 10 days, so halving the dose did not halve the effect. When it is used instead of TRT, the AUA's first blood test comes no sooner than 4 weeks after starting. [1], [29], [15]
This guide does not teach how to judge symptoms blamed on estrogen at home. The Academy note below covers a structured way to think them through before any add-on medicine.
Where do anastrozole protocols differ?
Most of the disagreement is not about the dose. It is about whether anastrozole belongs in a TRT plan at all, and that depends on which guideline you read and whether a man has symptoms or only a lab number.
Should anastrozole be added to TRT at all?
The guidelines that address it lean against routine use; practice is split.
| Source | Position on aromatase inhibitors for men on TRT |
|---|---|
| US Veterans Affairs 2026 | Not generally recommended, citing heart events, belly fat and bone loss |
| European urology guideline (EAU) 2026 | Off-label, poor evidence; long-term use can reduce bone density |
| AUA 2018 | For persistent breast symptoms with high estradiol: lower the testosterone dose if levels are upper-normal, otherwise consider an aromatase inhibitor; avoid long-term use |
| Endocrine Society 2018 | Estradiol is not part of routine monitoring |
| Brazilian societies 2026 | Routine estradiol monitoring not recommended; tamoxifen for breast growth |
| International Consultation on Sexual Medicine 2024 | Suggests not using aromatase inhibitors for low sexual desire |
| Survey of 489 clinicians (2020) | 69.4% treat high estradiol with symptoms, 47.7% treat it without symptoms, 14.4% prescribe it preventively |
[7], [41], [15], [58], [2], [37], [33]
A prescription written for one high estradiol result, with no symptoms, sits outside what these guidelines describe; under the one clinic's published criteria, only 44 of 1,708 men qualified. [3]
Which estradiol level calls for treatment?
There is no agreed number. The AUA suggests referring a man to an endocrinologist if estradiol is persistently above 40 pg/mL (about 147 pmol/L) before treatment, and acts on breast symptoms during it. The clinic series treated above 60 pg/mL, or 40–60 with breast tenderness. A fertility series added anastrozole above 50 pg/mL or when the testosterone-to-estradiol ratio fell below 10. A 2025 review says a testosterone-to-estradiol ratio of 10 to 30 "seems" beneficial but that no best value has been established. [15], [3], [32], [59]
The test itself adds doubt. Standard direct immunoassays read estradiol 6% to 74% higher than the more accurate mass spectrometry method in men, and the Endocrine Society says routine methods cannot measure men's low estradiol accurately. Units trip people up too: 1 pg/mL is about 3.67 pmol/L, so 40 pg/mL is about 147 pmol/L. See estrogen on TRT for assays, symptoms and timing. [60], [61], [62]
Lower the testosterone dose first?
The AUA's own path starts there: when breast symptoms persist with high estradiol and testosterone is upper-normal, it lowers the testosterone dose before any aromatase inhibitor. The reasoning is simple arithmetic: estradiol is made from testosterone, so a smaller testosterone dose makes less of it. How injection frequency and form affect estradiol is covered in estrogen on TRT and TRT dosage. [15]
Daily, twice a week or less often?
In the trial of older men, 1 mg twice a week lowered estradiol as much as 1 mg daily (both to 17 pg/mL), with a smaller testosterone rise. In young males, 0.5 mg daily lowered estradiol about as much as 1 mg. No trial in men has tested 1 mg once a week, doses of 0.25 mg or less, or timing doses to injection days, and no study has checked how evenly a cut tablet splits. The 1-mg-weekly-to-1-mg-daily spread in the clinician survey reflects that gap. [16], [29], [33], [10]
Does a low testosterone-to-estradiol ratio predict who benefits?
For fertility, sources disagree. An early series chose men for treatment because their testosterone-to-estradiol ratio was low. A 2023 study of 90 men found that baseline estradiol and the estradiol-to-testosterone ratio did not predict whose sperm improved; a high testosterone-to-LH ratio and having some sperm to start with did. [46], [30]
Anastrozole or tamoxifen for breast symptoms?
They work differently: anastrozole lowers estradiol throughout the body, while tamoxifen leaves estradiol high and blocks its effect in breast tissue. In the head-to-head trial in men on bicalutamide, tamoxifen prevented far more breast growth (10% vs 51%). They should not be taken together (interactions). See the tamoxifen guide. [34], [23]
What happens when you stop anastrozole?
The drug clears within days, and estradiol comes back as it does. [1], [11]
- The drug itself. With a half-life of 40–50 hours, most of it is gone within about a week. In women, estradiol stayed suppressed for up to 6 days after stopping daily 1 mg. No study has measured this in men on TRT. [11], [1]
- Estradiol. It returns toward the level set by the testosterone dose. No study has tested whether a rebound, a taper or a set recheck date after stopping is needed; labels give no tapering instructions. [1]
- Testosterone, when anastrozole was used instead of TRT. The trials measured the rise only while men were taking it; no study has followed men after stopping. [17], [16]
For stopping testosterone itself, see stopping TRT.
How is anastrozole taken, and how long does it last?
Anastrozole is swallowed. It comes only as a 1 mg tablet, it can be taken with or without food, and one dose keeps working for days. [1]
How long does anastrozole last in the body?
In women, blood levels peak about 2 hours after a dose; in a small study of 18 healthy men given a single 1 mg dose, the peak came at about 1.5 hours. Food lowers the peak by 16% and delays it to about 5 hours, without changing the total absorbed. [1], [63]
The half-life is about 50 hours on the US label and 40–50 hours on the UK label; the male study measured 41–46 hours. With daily dosing, levels climb for about 7 days to a steady state 3 to 4 times higher than after a single dose. About 85% is cleared by the liver and about 10% by the kidneys. [1], [11], [63]
Can an anastrozole tablet be split?
The labels describe a white, film-coated, round tablet that is not scored, and none gives splitting instructions or tests how evenly the pieces divide. A quarter tablet is therefore an estimate, not a measured 0.25 mg, and small errors matter more at small doses. Compounded lower-strength capsules or liquids are sometimes offered instead; compounded drugs are not FDA-approved, which means FDA does not check their safety, effectiveness or quality. [1], [10], [11], [64]
How should anastrozole be stored?
Store it at room temperature in its original pack. Each product's label sets its own details, so the leaflet in your box is the final word. [1], [11], [25]
| Product | Storage | Shelf life |
|---|---|---|
| Arimidex and US generics | 20–25 °C | Printed expiry date |
| Arimidex (UK) | Do not store above 30 °C | 5 years |
| Sun generic (UK) | No special storage conditions | Printed expiry date |
| Arimidex (Canada) | 15–30 °C | Printed expiry date |
For carrying medicines across borders, see traveling with testosterone.
What does anastrozole do to fertility, estrogen and red blood cells?
Each of these has its own hub guide. Here is what is specific to anastrozole.
Fertility. Used instead of testosterone, it raises LH and FSH and improved sperm counts in some men with low testosterone and low counts; taken alongside TRT, it does not protect sperm production (details above). See TRT and fertility. [16], [47], [24]
Estrogen. It lowers estradiol by roughly a third to two thirds in men: from 26 to 17 pg/mL in older men not on TRT, and from a median of 65 to 22 pg/mL in the on-TRT clinic series. That is its purpose and its main risk. See estrogen on TRT. [29], [16], [3], [5]
Red blood cells. Hematocrit did not change in the 12-week or 1-year trials of anastrozole instead of TRT; in 51 men on clomiphene plus anastrozole, 2 had hematocrit above 54%. Men on TRT keep the usual checks; see hematocrit on TRT. [16], [17], [32]
What do we actually know about anastrozole in men?
A fair amount about what it does to hormones, a little about fertility, and almost nothing from trials about adding it to TRT.

What did the randomized trials in men find?
| Study | Who and what | What it found | What it cannot show |
|---|---|---|---|
| Leder 2004 (controlled trial) | 37 men aged 62–74; 1 mg daily, 1 mg twice weekly or placebo, 12 weeks | Testosterone up (343 → 572 ng/dL, about 12 → 20 nmol/L, on 1 mg daily); estradiol down; no change in quality of life, erections or hematocrit; PSA rose on twice weekly | Men on TRT; long-term effects [16] |
| Burnett-Bowie 2009 | 88 men aged 60+; 1 mg daily or placebo, 1 year | Testosterone up; no gain in body composition or strength; spine bone density fell (in the 69-man bone analysis) | Men on TRT; fractures [17], [22] |
| Dias 2016 | 43 men aged 65–82; testosterone gel, anastrozole or placebo, 12 months | Both raised testosterone; only gel improved spine bone density and fast walking speed; lean mass rose only on anastrozole | Men on TRT; small [6] |
| Herzog 2010 | 40 men with epilepsy on testosterone injections; anastrozole or placebo added, 3 months | Sexual function normal in 72.2% vs 47.4%, not significant | Men without epilepsy; dose not in abstract [31] |
| Gibb 2016 (crossover trial) | 17 healthy men; 1 mg daily and placebo in turn, 6 weeks each | Estradiol fell and insulin sensitivity got worse | Long-term effects [66] |
The trials are small, short and mostly in older men not on TRT; the research trial with testosterone and the clomiphene comparison are described above. They agree on one thing: anastrozole moves hormone numbers reliably, and those numbers have not translated into measured benefits. [17], [16], [6]

Anastrozole used instead of testosterone in older men
Randomized trials in older men with low or borderline testosterone who were not on TRT.
BeforeAfter
Leder 2004: 12 weeks, 37 men aged 62–74
- 1 mg daily: testosterone rose
- 343 to 572 ng/dL
- 1 mg daily: estradiol fell
- 26 to 17 pg/mL
- 1 mg twice a week: testosterone rose
- 397 to 520 ng/dL
- 1 mg twice a week: estradiol fell
- 27 to 17 pg/mL
Quality of life, erections, urinary symptoms and hematocrit did not change. PSA rose from 1.7 to 2.2 ng/mL in the twice-a-week group only.
Burnett-Bowie 2009: 1 year, 69 men aged 60+
- Anastrozole 1 mg daily: spine bone density fell
- 1.121 to 1.102 g/cm² (−0.019)
- Placebo: spine bone density rose slightly
- 1.180 to 1.189 g/cm² (+0.009)
Difference between groups: P = 0.0014.
Did not change (Burnett-Bowie 2009, 88 men, 1 year)
- Body composition
- Strength
- PSA
- Urinary symptoms
- Hematocrit
- Lipids
Hormone numbers moved; measured benefits did not follow, and spine bone density fell.
The on-TRT clinic series, the pellet study and the fertility series report changes without control groups, so some improvement may have happened anyway, and the clinician survey shows how often anastrozole is prescribed, not whether it helps. [3], [21], [19], [33]
What is still unknown?
- Whether adding anastrozole to TRT improves how men feel, beyond one small trial in men with epilepsy.
- What it does to bone over more than a year, and whether it raises fracture risk in men.
- Its effect on heart rhythm, heart events or mood in men on TRT: no study has isolated it.
- The right dose, if any, for men on TRT, and whether low intermittent doses or cut tablets behave predictably.
How does anastrozole work?
Anastrozole blocks aromatase, the enzyme that turns testosterone into estradiol and androstenedione into estrone. It binds reversibly: when the drug clears, the enzyme works again. Exemestane, a related drug, binds permanently, so the body has to make new enzyme. [4], [1]
Where men's estradiol comes from. Men make about 35–45 micrograms of estradiol a day. About 20% comes straight from the testicles, and most of the rest is made by converting testosterone and related hormones in fat tissue, muscle, brain, bone and other tissues. Aromatase is also active in fat tissue, and in one fertility practice, men with obesity and higher starting estradiol were more likely to have anastrozole added. [4], [67]
Why it raises testosterone off TRT but not on it. Estradiol acts as a brake on both the hypothalamus and the pituitary. Lowering it releases the brake: LH rises, and working testicles make more testosterone. On full-dose TRT the brake is largely on from the prescribed testosterone, so estradiol falls and, in the one clinic series, testosterone stayed where the dose put it. With waning pellets, one records review found that adding anastrozole kept testosterone up longer. [28], [16], [3], [21]

The same tablet, off TRT and on TRT
Before and after anastrozole in two different studies. Each marker uses the same scale in both.
BeforeAfter
Off TRT: Leder 2004
Randomized trial, 12 older men, 1 mg daily for 12 weeks (means).
- Estradiol fell
- 26 to 17 pg/mL
- LH rose
- 5.1 to 7.9 U/L
- Testosterone rose
- 343 to 572 ng/dL
On TRT: Punjani 2021
Clinic records, 44 men, 0.5 mg three times a week (medians).
- Estradiol fell
- 65 to 22 pg/mL
- Testosterone stayed the same
- 616 and 596 ng/dL
LH was measured and did not change significantly (values not published). Different men, doses and study types; not a head-to-head comparison.
Off TRT it raised testosterone; on TRT it only lowered estradiol.
How strong the effect is. In men, drugs like anastrozole lower the estradiol-to-testosterone ratio by about 77% and do not suppress estradiol completely, probably because men have far more testosterone, the raw material for estradiol, in their blood. It does not affect the adrenal hormones cortisol or aldosterone, and it does not block estrogen receptors; that is what tamoxifen does. [4], [11], [1]
Why bone is the main concern. In men, estradiol made from testosterone is what keeps bone strong. In the trial comparing gel with anastrozole, both raised testosterone, but only the gel, which also raises estradiol, improved spine bone density. Men born without working aromatase have very low bone mass. [6], [4]
What are the risks and unanswered questions?
Is anastrozole safe?
For a short, supervised course it is usually tolerated, but lowering estradiol has real costs in men: weaker bones, more body fat and lower sex drive when estradiol goes too low. Most label safety data come from women with breast cancer taking it for years, and no long-term safety study exists in men on TRT. [22], [5], [1]
What side effects do the labels list?
In the large breast cancer trial that compared anastrozole with tamoxifen in about 6,200 women (3,092 on anastrozole and 3,094 on tamoxifen), the US label reports:
| Effect | Anastrozole | Tamoxifen |
|---|---|---|
| Joint symptoms (aches, stiffness, arthritis) | 36% | 29% |
| High blood pressure | 13% | 11% |
| Depression | 13% | 12% |
| Osteoporosis | 11% | 7% |
| Any fracture | 10% | 7% |
| Insomnia | 10% | 9% |
| High cholesterol | 9% | 3.5% |
| Weight gain | 9% | 9% |
Hot flashes, headache, nausea, rash and weakness are also common in women, and the UK label lists hair thinning as common and trigger finger as uncommon. Tendon problems, including tendon rupture, have been reported after marketing. The 2026 Brazilian statement lists these possible effects in men: high blood pressure, higher PSA, headaches, lower bone density, joint and muscle pain, fatigue, mood changes, raised liver enzymes, higher hematocrit and higher LDL cholesterol. [1], [11], [2]
What happens when estradiol goes too low?
What is measured in men:
- Body fat and sex drive. When researchers lowered men's hormones on purpose, missing estradiol mainly caused fat gain, and both testosterone and estradiol contributed to sexual function. [5]
- Libido. In a randomized trial of 296 infertile men, lower libido was reported by 18 of 147 on letrozole, another aromatase inhibitor, against 8 of 149 without it. [68]
- Blood sugar. Six weeks of 1 mg daily made insulin work less well in healthy men. [66]
- Memory. In older men given testosterone, verbal memory improved only when estradiol was allowed to rise. [20]
Joint pain, low mood and poor sleep are label effects in women and common complaints in men's forums, but they have not been measured in trials of men on TRT. On-TRT accounts of "crashed" estradiol are described in the community section. [1]
Does anastrozole weaken bones?
In older men it lowered spine bone density within a year, and long-term male data do not exist. In 69 men aged 60 and older, a year of 1 mg daily lowered spine bone density from 1.121 to 1.102 g/cm², while it rose from 1.180 to 1.189 g/cm² on placebo. Other sites moved the same way without reaching statistical significance. [22]
- A meta-analysis found spine bone density lower after 6 months on an aromatase inhibitor. [69]
- An investigational aromatase inhibitor lowered spine bone density by 1.2% to 2.1% over 24 weeks, against a 0.7% rise on placebo. [39]
- In the UK regulator's reading of the trial in boys with growth hormone deficiency, fractures were more common on anastrozole. [11]
The labels warn that it can lower bone density and advise considering bone density checks; the AUA says aromatase inhibitors should in general not be used for long periods because of bone loss, and the Brazilian statement rules them out with osteoporosis or marked osteopenia. No study has counted fractures in adult men. [1], [15], [2]

Does anastrozole affect the heart, cholesterol or blood sugar?
In women with existing heart disease, heart events were more common on anastrozole; in men, the short trials found no change in cholesterol, and no heart-outcome study exists. [1], [17]
- Heart events (women). In the 465 of 6,186 women who already had ischemic heart disease (heart disease caused by narrowed arteries), ischemic heart and blood-vessel events occurred in 17% of the 216 on anastrozole and 10% of the 249 on tamoxifen. [1]
- Cholesterol. In women, high cholesterol was reported in 9% on anastrozole vs 3.5% on tamoxifen (3,092 vs 3,094 women), and in two earlier trials in advanced breast cancer, average total cholesterol rose by about 0.5 mmol/L on anastrozole; a later label trial found no meaningful change in LDL or HDL over 12 months. In older men, fasting lipids did not change over 12 weeks or 1 year, and in the epilepsy trial triglycerides fell with anastrozole. [1], [70], [17], [31]
- Blood sugar. Insulin sensitivity got worse in healthy men over 6 weeks, but did not change over 12 weeks or 12 months in older men with low testosterone. [66], [70], [71]
The VA cites heart events, belly fat and bone loss as its reasons against routine use. Atrial fibrillation comes up in forums, but no study has linked it to anastrozole. [7]
For testosterone itself, the best heart evidence is TRAVERSE, a trial of about 5,200 men at high heart risk given testosterone gel or placebo gel; it did not test anastrozole. Heart attack, stroke or heart death occurred in 182 of 2,596 men on testosterone (7.0%) vs 190 of 2,602 on placebo (7.3%) (hazard ratio 0.96, a measure of relative risk), meeting its safety margin, while atrial fibrillation (3.5% vs 2.4%), acute kidney injury (2.3% vs 1.5%) and lung clots (0.9% vs 0.5%) were more common. In TRAVERSE, clinical fractures were more common on testosterone (3.50% vs 2.46%; 91 of 2,601 vs 64 of 2,603 men; hazard ratio 1.43), so testosterone did not protect bone. It tested only a gel, men used it for 21.7 months on average and about 61% stopped early. See TRT and heart health. [72], [73], [74]
Could anastrozole affect the prostate?
In the 12-week trial, PSA (prostate-specific antigen, a prostate blood test) rose from 1.7 to 2.2 ng/mL in the twice-weekly group only; in the 1-year trial, PSA and urinary symptoms did not change. The Brazilian statement lists a PSA rise among possible effects. Prostate checks on TRT continue as usual; see TRT and the prostate. [16], [17], [2]
Is anastrozole legal? Is it FDA approved?
Checked September 2026. Rules differ by country and change often.
- United States. Anastrozole is FDA-approved as a prescription medicine for breast cancer in women after menopause, first as Arimidex on December 27, 1995; the brand is now sold by ANI Pharmaceuticals, and generics are marketed. It is not a controlled substance: DailyMed lists no DEA schedule, and it is absent from the DEA's controlled substances list dated August 27, 2026. Every use in men is off-label. FDA's drug shortage data list no anastrozole shortage (updated September 26, 2026). [8], [9], [75], [15], [76]
- Canada. Prescription-only (on the Prescription Drug List). On September 28, 2026, Health Canada's Drug Product Database listed 18 anastrozole products as marketed: Arimidex and 17 generics. The monograph covers breast cancer in women after menopause only. [77], [12], [25]
- United Kingdom. A prescription-only medicine, licensed for breast cancer treatment and prevention in women after menopause. [11]
- Australia. Prescription-only (Schedule 4). The Pharmaceutical Benefits Scheme subsidizes it only for breast cancer, so a man's prescription is not subsidized. [13], [14]
- European Union. Authorized country by country; a 2011 European review harmonized the Arimidex product information, for breast cancer in women after menopause only. [26]
Buying anastrozole labeled "for research use only" does not make it legal, tested or the same as a licensed medicine.
What it costs. It is inexpensive as a generic. In September 2026 US pharmacies paid about $0.14 per generic tablet and about $52.86 per Arimidex tablet (the average acquisition cost, not the retail price). The NHS reimbursement price in England was 105 pence for 28 tablets, and the Australian subsidized price for breast cancer was A$20.77 for 30 tablets. [78], [79], [14]
Is anastrozole banned in sport?
Yes. Aromatase inhibitors, anastrozole included, are in class S4.1 of the World Anti-Doping Agency (WADA) Prohibited List, banned in and out of competition, and the 2027 list keeps them banned from January 1, 2027. [80], [81]
Who should be especially cautious?
- Men with osteoporosis or thin bones, or at high fracture risk. The Brazilian statement rules it out with osteoporosis or marked osteopenia, and bone density fell in older men. [2], [22]
- Men with severe liver disease. A contraindication in the Brazilian statement; the UK label advises caution with moderate to severe liver impairment. [2], [11]
- Men with normal or low estradiol, or no symptoms, since the measured harms in men come from lowering it (low estradiol). [5]
- Men with existing heart disease, diabetes or insulin resistance. Heart events were more common in women with heart disease, and insulin sensitivity fell in healthy men. [1], [66]
- Men who want children while on TRT. Anastrozole does not protect sperm production on testosterone (fertility). [24]
- Men taking tamoxifen or estrogen-containing medicines (see the next question).
- Children and teenagers. The UK label says it is not recommended for children and adolescents; any use is specialist care. [11]
- Drug-tested athletes. Banned at all times. [80]
- Women who are pregnant or breastfeeding. It is contraindicated and can harm an unborn baby; these guides are for men. [11], [1]
Can anastrozole be taken with other medicines?
The labels list few interactions:
- Tamoxifen: do not combine. Taking both lowered anastrozole levels by 27% in a large trial. The UK anastrozole label says to avoid the combination, and the US tamoxifen label says the two should not be given together. [23], [11], [82]
- Estrogen-containing medicines may weaken its effect and should not be used with it. [1]
- Warfarin. In 16 male volunteers, anastrozole did not change warfarin levels or clotting. [1]
hCG. hCG makes the testicles produce testosterone and some estradiol. One review reports that letrozole worked almost as well (81% vs 77% lower estradiol-to-testosterone ratio) when the testicles' own hormone output was suppressed, so the testicles do not seem to explain the incomplete effect; no trial found for this guide tested anastrozole together with hCG. See hCG. [4]
Supplements. Evidence that supplements lower estradiol in men is very thin. One small study of 8 healthy men, with no separate control group, found estradiol fell after a week of 10 mg of boron a day. No trial found for this guide tested boron, DIM, calcium D-glucarate or zinc in men on TRT, so none can be called a substitute. [83] See the DIM, calcium D-glucarate, zinc and boron guides for what is known about each. Bring a full list of everything you take to a pharmacist or prescriber.
What should be monitored while taking anastrozole?
The US label advises considering bone density and cholesterol monitoring. The AUA adds estradiol and testosterone checks when anastrozole is used instead of testosterone. No guideline sets a testing schedule for men taking it with TRT. Use this summary to prepare questions for your prescriber; it is not a personal testing plan. [1], [15]
| Why it matters | What labels and guidelines say | Tracking category |
|---|---|---|
| Estradiol | AUA: adjust to keep it in range; stop if it stays high; first check no sooner than 4 weeks. Brazilian statement: routine estradiol checks on TRT not recommended. Immunoassays can read high in men | Blood work; Hormonal Symptoms; Fluid Retention |
| Testosterone and LH (when used instead of TRT) | AUA: first check no sooner than 4 weeks after starting | Blood work; Libido; Energy Levels |
| Bone | US label: consider bone density monitoring. AUA: avoid long-term use. Brazilian statement: not with osteoporosis | Bone Health (bone density result) |
| Cholesterol | US label: consider cholesterol monitoring | Blood work |
| Symptoms of low estradiol | Women's label lists joint disorders, depression and hot flashes. In men, lowering estradiol on purpose caused fat gain and affected sexual function; no trial measured these on TRT [1], [5] | Joint Health; Mood & Wellbeing; Libido; Energy Levels |
| TRT markers | Hematocrit, PSA and testosterone monitoring continue as for any TRT | Blood work |
See TRT blood work. When anastrozole starts, stops or changes, note the date, and record when the last tablet and last testosterone dose were taken before each draw. [1]
What do people in public communities report?
Public forums hold every kind of anastrozole story: men who felt better within a day, men who felt worse within a day, and many more asking whether to take a prescription at all. The accounts below come from public Reddit threads posted between September 2025 and September 2026, described without identifying anyone. Threads about non-prescribed steroid cycles appear only where they show something about anastrozole itself, and are marked.
Why are men offered anastrozole?
In most threads, the prescription followed a lab number rather than a symptom. One man felt good after starting TRT, with estradiol at 50; his doctor raised his testosterone to 140 mg a week and added 1 mg of anastrozole weekly anyway. After the second dose his sex drive and erections worsened, his estradiol tested below 5, and he skipped the next dose. [84]
Others paused. A man who felt much better after losing 100 pounds on TRT was prescribed 1 mg every 48 hours for an estradiol of 59.7 with no symptoms, and planned to ask about repeating the labs. Another, offered 0.5 mg for an estradiol of 40 pg/mL a month into weekly injections, chose instead to split his dose into two injections and retest. [85], [86]
What do "crashed estradiol" stories look like?
This is the most common harm described, and the numbers in several accounts back it up.
- Weekly 1 mg for a mild result. A man who felt fairly good on 100 mg a week was given 1 mg weekly for an estradiol of 43 without symptoms. His energy and libido dropped after the first dose; later, estradiol was below the lab's measurable limit, with aches, poor sleep and irritability. His hematocrit had also reached 60%, which he blamed on anastrozole and a reply disputed. [87]
- Daily 1 mg with pellets. After a little over a month of 1 mg daily, a man on pellets developed fatigue and anxiety, and his estradiol came back below the reportable range. [88]
- Five doses were enough. Another man took 0.5 mg twice a week for an estradiol of about 60 with no clear symptoms. Within about two weeks he described severe fatigue, poor sleep and a loss of desire and erections, stopped the tablets and lowered his testosterone. [89]
One man put the opposite side plainly: after five months on 200 mg a week with 1 mg of anastrozole weekly from the start, he blamed joint pain, erection problems and low mood on the tablet, stopped it with his prescriber's agreement and felt much better. Three weeks later his estradiol was 66, and the prescriber asked him to restart based on the number. [90]
What do the positive reports look like?
Some men describe clear relief, usually when there were symptoms to begin with:
- A man on 120 mg a week with bloating, nipple sensitivity and sexual problems said these eased quickly on 0.5 mg a week, then planned to split both his testosterone and his anastrozole into twice-weekly doses and retest before trying to stop it. [91]
- A man whose sleep and anxiety worsened after adding hCG, with estradiol at 85 pg/mL, described much deeper sleep within two days of anastrozole. He had not rechecked his estradiol when he posted. [92]
- Itchy nipples at an estradiol of 55 pg/mL mostly settled for one man taking 0.5 mg every two to three days, less than his doctor had prescribed. [93]
None of these men reported a follow-up over months.
Why is it so hard to tell what helped?
Because two things usually change at once. A man with chest acne on 200 mg a week lowered his dose to 160 mg and started an aromatase inhibitor in the same week. The acne improved, but his libido and morning erections disappeared, and he could not tell which change was responsible; he planned to stop the tablet and keep the lower dose. [94]
Another man felt his best on 60 mg a week; when his doctor raised it to 100 mg and added 0.5 mg of anastrozole weekly, the benefits faded, and two weeks after stopping the tablet he could not tell whether it, the higher dose or simply time was to blame. [95]
A single dose can look like proof in either direction. One man on 125 mg a week felt better sleep and erections for one night after 0.25 mg, then the problems returned. [96]
What do people say about finding a dose?
Dose-finding runs into the 1 mg tablet:
- Cutting tablets. One man found it hard to divide unscored 1 mg tablets into consistent quarters and bought a second pill cutter. [91]
- Very small doses. Another, who had felt awful when estradiol went too low before, tried 0.03125 mg (a thirty-second of a tablet) on one night a week. [97]
- Too much, then too little. A man with a big estradiol rise felt low-estradiol symptoms on 0.25 mg three times a week and high-estradiol symptoms on 0.125 mg twice a week, and was still searching. [98]
- Unit mistakes. One man first wrote his dose as 6.25 mg, then 25 mg, before correcting it to 0.25 mg twice a week. [99]
Timing confuses results too. One man's estradiol of 28 was drawn two days after a dose of anastrozole, so it could not show his usual level. [100]
Which other problems do people blame on anastrozole?
Several threads blame anastrozole for problems the thread cannot settle:
- Heart rhythm. A man on 0.5 mg twice a week developed atrial fibrillation for the first time after a stressful week; his cardiologist attributed it to stress. [101]
- Lasting sexual symptoms. One man described the same episode across three threads: genital numbness and sexual dysfunction starting after a single 0.25 mg dose, taken hours after a testosterone-booster supplement and during a two-week break from his TRT. His later estradiol results were not low, and replies questioned the explanation. [102], [103], [104]
- Hair shedding. A man took 0.25 mg every two days for 15 days and then had heavy shedding for over a month. His weekly estradiol results fell only from 85 to 65 pg/mL, which he pointed out was not a crash. [105]
- Cholesterol. A man on testosterone, hCG and anastrozole noted HDL (the "good" cholesterol) of 39.7 mg/dL, against about 55–57 before treatment, and wondered which drug was responsible. [106]
- A bad reaction to a first dose. After one 0.5 mg dose for nipple sensitivity, one man described hot flashes, flushing, palpitations and higher blood pressure for a couple of days and did not take a second dose. [107]
These are single accounts. None shows that anastrozole caused the problem, and none shows that it did not.
What about anastrozole without TRT?
Some men take it with clomiphene or enclomiphene instead of testosterone. One described less brain fog and better erections after three months, while starting weight training at the same time. Another, trying for a child, stopped 1 mg twice a week because of joint pain, felt very well on 0.25 mg twice a week, and asked whether an estradiol of 90 meant he should take more; replies suggested judging by symptoms. [108], [109]
Threads about steroid cycles, with doses far above replacement, are outside this guide (TRT vs steroids). One shows the drug's limits: a man on a 460 mg weekly cycle added anastrozole for a tender breast lump, which felt slightly larger two days later. (Steroid cycle.) [110]
How can you judge an anastrozole story?
Ask: Were there symptoms, or only a lab number? Which estradiol test was used, and how long after the last testosterone injection and the last tablet was blood drawn? What was the dose in milligrams, and how was the tablet cut? What else changed at the same time, such as the testosterone dose, hCG, weight loss or training? And what happened a few months later?
These selected discussions show what people experience and the questions research has not answered. They are not a survey of all users, a success rate or a substitute for the studies.
How does anastrozole compare with other options?
These are the options most often weighed against anastrozole by men on TRT. Status was checked in September 2026.
| Option | What it is | What it does to estradiol | What stands out | US status |
|---|---|---|---|---|
| Anastrozole (this guide) | Nonsteroidal aromatase inhibitor, 1 mg tablet | Lowers it | Lowered spine bone density in older men; weaker than tamoxifen for breast growth | Approved for breast cancer in women [1], [22] |
| Letrozole | Nonsteroidal aromatase inhibitor | Lowers it | Half-life about 2 days; lower libido in a fertility trial (18 of 147 vs 8 of 149) | Approved for breast cancer in women [111], [68] |
| Exemestane | Steroidal aromatase inhibitor that binds permanently | Lowers it | Half-life about 24 hours; bone warning | Approved for breast cancer in women [112] |
| Tamoxifen | SERM: blocks estrogen in breast tissue and at the brain | Raises it | Best-tested for breast growth caused by prostate cancer drugs; clot risk; do not combine with anastrozole | Approved for breast cancer [82], [34] |
| Clomiphene and enclomiphene | SERMs used instead of TRT | Raises it | Raised testosterone more than anastrozole in a head-to-head trial | Clomiphene approved for women's ovulation problems; enclomiphene has no FDA approval (it is on FDA's interim compounding list, which is not an approval) and was refused in the EU in 2018 [113], [114], [115], [18] |
| A lower testosterone dose | Changing the TRT itself | Lowers it, because less testosterone is converted | The AUA's first step for breast symptoms when testosterone is upper-normal | Not applicable [15] |
No trial has compared these options in men on TRT. See estrogen on TRT for the full picture.
Common questions about anastrozole
Do I need an aromatase inhibitor on TRT?
Usually not. Most men on TRT would not qualify under the guidelines that address it: the VA does not generally recommend aromatase inhibitors, the European urology guideline calls the evidence poor, and the AUA reserves them for persistent breast symptoms with high estradiol. Under one clinic's published criteria, only 44 of 1,708 men qualified. [7], [41], [15], [3] See should it be added.
What dose of anastrozole is used on TRT?
No label or major guideline gives one. The only published on-TRT clinic schedule is 0.5 mg three times a week, adjusted to keep estradiol at 20–40 pg/mL, and a clinician survey found starting doses from 1 mg a week to 1 mg a day. The guideline ranges (AUA 0.05–1 mg every 1–3 days as printed; Brazil 0.5–1 mg daily or every other day) are for use instead of testosterone. [3], [33], [15], [2] See typical protocols.
Should I target a specific estradiol number?
No guideline sets an estradiol target for men on TRT. The AUA acts on breast symptoms with high estradiol and suggests referral if estradiol is persistently above 40 pg/mL before treatment; the Brazilian statement advises against routine estradiol checks on TRT. Standard immunoassays can also read men's estradiol too high. [15], [2], [60] See which level.
What happens if anastrozole lowers estradiol too far?
In men, low estradiol is linked to fat gain, lower sex drive and poorer insulin sensitivity, and over time weaker bones. When it stops, the drug clears within about a week (its half-life is about 2 days); in women, estradiol stayed suppressed for up to 6 days after stopping. Report symptoms to your prescriber rather than adjusting doses on your own. [5], [66], [22], [1] See low estradiol.
Is anastrozole safe to take long term?
Its long-term safety in men has not been studied. A year of 1 mg daily lowered spine bone density in older men, and the AUA says aromatase inhibitors should in general not be used for long periods. The labels advise considering bone density and cholesterol checks. [22], [15], [1] See bone.
Can I use anastrozole instead of TRT?
It can raise testosterone in men whose testicles and pituitary work, and some guidelines list it as an off-label option for men who want to keep fertility. But in the largest year-long placebo-controlled trial, body composition and strength did not change and spine bone density fell; a smaller trial saw lean mass rise about 1.2–1.5 kg from baseline, while only testosterone gel improved bone and walking speed. Clomiphene raised testosterone more in a head-to-head trial. [16], [17], [15], [18] See instead of TRT.
Can I cut a 1 mg tablet into quarters?
The labels describe an unscored, film-coated tablet and give no splitting instructions or data on how evenly it divides, so a quarter is an estimate rather than a measured 0.25 mg. Compounded lower-strength versions are not FDA-approved. Ask your prescriber or pharmacist before changing how you take it. [10], [11], [64] See tablets.
Is anastrozole a steroid, a controlled drug or banned in sport?
It is not a steroid, and it is not a controlled substance in the US; everywhere covered here it is a prescription-only medicine. It is banned in sport at all times (WADA class S4.1). [1], [9], [13], [80] See legal status.
Glossary
Plain explanations of the medical, dosing and research terms used in this guide. Underlined terms in the text link here.
- Aromatase
- The enzyme that turns testosterone into estradiol (and androstenedione into estrone). It is found in fat tissue, the testicles, the brain and bone.
- Aromatase inhibitor
- A medicine, such as anastrozole, letrozole or exemestane, that blocks the enzyme that turns testosterone into estradiol, so estradiol falls.
- Azoospermia
- No sperm at all in a semen sample.
- Bone mineral density
- A measure of how much mineral is packed into bone, usually taken with a low-dose X-ray scan (DXA) of the spine and hip. Lower values mean weaker bone.
- Controlled trial
- A study that compares people who receive a treatment with a similar group who do not, often receiving a placebo instead. Randomly assigning people to each group makes the comparison fairer.
- Dose (amount each time)
- The amount given on one occasion. A protocol lists both the dose and how often it is given.
- Estradiol
- The main form of estrogen. In men it is made mostly from testosterone and helps keep bones strong, control body fat and support sex drive.
- FSH (follicle-stimulating hormone)
- A pituitary hormone that supports sperm production. Anastrozole raises it in men not on TRT; testosterone therapy lowers it.
- GnRH agonist
- A medicine that, given continuously, shuts down the pituitary's LH and FSH signals. It is paired with an aromatase inhibitor in male breast cancer.
- Gynecomastia
- Growth of breast tissue in men, often tender at first. It is linked to a higher estrogen-to-testosterone balance.
- Half-life
- The time it takes for the level of a substance in the blood to fall by half. For anastrozole it is about 50 hours. It is not the same as how long an effect lasts.
- Hematocrit
- The share of the blood made up of red blood cells. Testosterone therapy can raise it, which is why it is checked.
- Immunoassay
- A common, inexpensive lab method that measures a hormone using antibodies. For the low estradiol levels in men, direct immunoassays can read too high.
- Mass spectrometry (LC-MS/MS)
- A more accurate lab method that measures a hormone by its molecular weight. It is often labeled a "sensitive" estradiol test.
- LH (luteinizing hormone)
- A pituitary hormone that tells the testicles to make testosterone. Anastrozole raises it in men not on TRT; testosterone therapy switches it off.
- Meta-analysis and systematic review
- A systematic review gathers all studies on a question in a planned way. A meta-analysis combines their results statistically.
- Off-label use
- Prescribing an approved medicine for a use, dose or group of people that its label does not cover. It is legal for prescribers but means the regulator has not reviewed evidence for that use.
- Osteopenia and osteoporosis
- Osteopenia is bone density below normal; osteoporosis is thinner, weaker bone with a higher chance of breaking.
- Post-cycle therapy (PCT)
- Drugs taken after an anabolic-steroid cycle to try to speed the return of the body's own testosterone. The schedules used online have not been tested in trials.
- Placebo
- A dummy treatment with no active ingredient, used as a comparison in studies.
- Primary hypogonadism
- Low testosterone because the testicles themselves do not work well, even though the pituitary sends plenty of LH and FSH. Anastrozole cannot raise testosterone here.
- PSA (prostate-specific antigen)
- A blood test for a protein made by the prostate, used to decide whether prostate checks are needed.
- SERM (selective estrogen receptor modulator)
- A tablet, such as tamoxifen, clomiphene or enclomiphene, that blocks estrogen's action in some tissues rather than lowering estrogen. At the brain it blocks estrogen's feedback, so the pituitary releases more LH and FSH.
- Steady state
- The point, after repeated doses, when the amount taken in matches the amount cleared, so blood levels stop climbing. For daily anastrozole it takes about 7 days.
- Testosterone-to-estradiol ratio
- Total testosterone (in ng/dL) divided by estradiol (in pg/mL). Some fertility studies selected men with a ratio below 10; no best value has been established.
- Titration
- Adjusting a dose in steps, usually based on blood tests and symptoms.
- TRT (testosterone replacement therapy)
- Prescribed testosterone, by injection, gel or other forms, for men with low testosterone. It switches off the brain's LH and FSH signals.
- WADA
- The World Anti-Doping Agency, which publishes the list of substances banned in sport. Aromatase inhibitors are banned at all times.
- Weekly total
- All the amounts taken in one week, added together. For example, 0.5 mg three times a week is a 1.5 mg weekly total.
How this guide was researched
This guide is built from a thorough review of the sources cited throughout it: product labels from the United States, the United Kingdom and Canada, clinical guidelines from the United States, Canada, the United Kingdom, Europe and Brazil, published clinical trials and studies, and regulatory records from four countries. We also reviewed public online forums where men describe their own experiences with anastrozole.
The guide cites 115 sources, including 10 product labels, 15 clinical guidelines and position statements and 38 original studies in people, plus 27 public community threads. Each type of source answers a different question. Labels and guidelines show what is approved and what clinicians are told to do. Trials and studies show what was measured, and in whom. Personal accounts show what individual people experienced. Every numbered citation links to its entry below, labeled by source type.
How this guide was made
Research and drafting were AI-assisted. Every cited source was checked against the original, and the guide was reviewed and edited by Doserly before publication. It has not had an independent clinical review, and Doserly does not currently have medical reviewers. Doserly makes a medication and health-tracking app and runs Doserly Academy, both of which are promoted in this guide. Read our editorial policy for how guides are researched, updated and corrected.
This guide is for educational purposes. It summarizes what the reviewed sources report so the research is easier to understand; it is not medical advice. For a deeper dive, or to check any point for yourself, go straight to the cited sources.
Explore the sources
These are the documents cited in this guide. Labels, guidelines, studies and personal accounts answer different questions. A source being listed does not mean every statement on its page is endorsed.
Showing 115 sources
- 01
ARIMIDEX (anastrozole) tablets, for oral use: prescribing information ↗
Product label (US)
Full label reviewed.
Detail: 1 mg once daily; approved only for breast cancer in women after menopause; half-life about 50 hours; steady state in about 7 days; estradiol suppression lasted up to 6 days after stopping (women); bone and cholesterol warnings; ATAC side-effect table; not scored.
- 02
Care of Patients with Male Hypogonadism: Joint Position Statement (Brazilian Society of Endocrinology and Metabolism, Brazilian Society of Urology, Brazilian Association for Sexual Medicine and Health) ↗
Clinical practice guideline (Brazil)
Original full text reviewed.
Detail: Anastrozole 0.5–1 mg daily or on alternate days as an off-label alternative to testosterone; contraindicated with osteoporosis, significant osteopenia or severe liver disease; routine estradiol monitoring on TRT not recommended; tamoxifen for breast growth.
- 03
The Utilization and Impact of Aromatase Inhibitor Therapy in Men With Elevated Estradiol Levels on Testosterone Therapy ↗
Human report
Original full text reviewed.
Detail: 44 of 1,708 men met criteria; anastrozole 0.5 mg three times a week; median estradiol 65 → 22 pg/mL; testosterone 616 vs 596 ng/dL; symptoms, bone and side effects not reported.
- 04
Aromatase inhibitors in men: effects and therapeutic options ↗
Review
Original full text reviewed.
Detail: Men make 35–45 micrograms of estradiol a day; third-generation aromatase inhibitors cut the estradiol-to-testosterone ratio by about 77% in men; aromatase-deficient men have very low bone mass.
- 05
Gonadal steroids and body composition, strength, and sexual function in men ↗
Human trial
Original abstract reviewed.
Detail: When men's hormones were lowered experimentally, estradiol deficiency mainly caused fat gain; both hormones contributed to sexual function.
- 06
Effects of aromatase inhibition vs. testosterone in older men with low testosterone: randomized-controlled trial ↗
Human trial
Original abstract reviewed.
Detail: 43 men aged 65–82, 12 months: testosterone gel and anastrozole both raised testosterone; only gel improved spine bone density and fast gait speed; lean mass rose only on anastrozole.
- 07
Evaluation for and Management of Males with Low Testosterone: Recommendations for Use (January 2026) ↗
Health-system clinical recommendations (US)
Original full text reviewed.
Detail: Aromatase inhibitors not generally recommended for men on testosterone (heart events, central fat, bone loss).
- 08
Drugs@FDA: NDA 020541, ARIMIDEX (anastrozole) ↗
FDA approval record (US)
Structured data reviewed.
Detail: NDA 020541 approved December 27, 1995; now held by ANI; prescription.
- 09
DailyMed listing: ARIMIDEX (anastrozole) tablet, ANI Pharmaceuticals (listing metadata) ↗
Drug listing (US)
Original page reviewed.
Detail: US Arimidex listing: DEA schedule none; labeler ANI Pharmaceuticals.
- 10
Anastrozole tablets 1 mg (Breckenridge): prescribing information ↗
Product label (US)
Full label reviewed.
Detail: US generic 1 mg tablet, not scored; store at 20–25 °C.
- 11
Arimidex 1 mg film-coated tablets: Summary of Product Characteristics ↗
Product information (UK)
Full label reviewed.
Detail: 1 mg daily for breast cancer treatment and prevention in women after menopause; half-life 40–50 hours; contraindicated in pregnancy and breastfeeding; avoid with tamoxifen or estrogen; not recommended in children; the growth-hormone boys trial showed no height benefit and more fractures; do not store above 30 °C.
- 12
Drug Product Database: anastrozole products and status ↗
Drug product register (Canada)
Structured data reviewed.
Detail: 18 anastrozole products listed as marketed (Arimidex and 17 generics), all prescription.
- 13
Poisons Standard May 2026 (SUSMP): Schedule 4 entry for anastrozole ↗
Medicines scheduling (Australia)
Original index reviewed.
Detail: Anastrozole is Schedule 4 (prescription-only medicine).
- 14
PBS item 8179L: anastrozole 1 mg tablet, 30 ↗
Subsidy listing (Australia)
Original page reviewed.
Detail: Item 8179L: restricted to breast cancer; dispensed price A$20.77 for 30 tablets.
- 15
Evaluation and Management of Testosterone Deficiency: AUA Guideline ↗
Clinical practice guideline (US)
Original full text reviewed.
Detail: Table 6 lists anastrozole "0.05 - 1 mg every 1-3 days" as an alternative to testosterone, not FDA-approved in males; avoid long-term use (bone); stop if estradiol stays high; first check no sooner than 4 weeks; for persistent breast symptoms with high estradiol, lower the testosterone dose if upper-normal or consider an aromatase inhibitor.
- 16
Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels ↗
Human trial
Original abstract reviewed.
Detail: 37 men aged 62–74: 1 mg daily raised testosterone 343 → 572 ng/dL, 1 mg twice weekly 397 → 520; estradiol 26 → 17 and 27 → 17 pg/mL; no change in quality of life, erections, urinary symptoms or hematocrit; PSA rose on twice weekly.
- 17
Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial ↗
Human trial
Original abstract reviewed.
Detail: 88 men aged 60+, 1 mg daily for 1 year: testosterone 11.2 → 18.2 nmol/L at 3 months; no change in body composition, strength, PSA, hematocrit or lipids.
- 18
A Randomized Prospective Double-Blind Comparison Trial of Clomiphene Citrate and Anastrozole in Raising Testosterone in Hypogonadal Infertile Men ↗
Human trial
Original abstract reviewed.
Detail: 26 infertile men with low testosterone: clomiphene 25 mg raised testosterone more than anastrozole 1 mg over 12 weeks; neither changed semen or symptoms.
- 19
Efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index >=25 kg/m2 ↗
Human report
Original abstract reviewed.
Detail: 30 men with BMI 25+: testosterone 270.6 → 412 ng/dL; estradiol 32 → 15.9 pg/mL; sperm 7.8 → 14.2 million/mL; 14 pregnancies, 10 by IVF; no control group.
- 20
The role of aromatization in testosterone supplementation: effects on cognition in older men ↗
Human trial
Original abstract reviewed.
Detail: 60 healthy men aged 50–90, 6 weeks: testosterone raised estradiol 81%; adding anastrozole cut it 50%; verbal memory improved only where estradiol rose.
- 21
Coadministration of anastrozole sustains therapeutic testosterone levels in hypogonadal men undergoing testosterone pellet insertion ↗
Human report
Original abstract reviewed.
Detail: 38 men on testosterone pellets: anastrozole 1 mg daily kept estradiol lower; reinsertion about 198 vs 128 days.
- 22
Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels ↗
Human trial
Original abstract reviewed.
Detail: 69 men aged 60+, 1 mg daily for 1 year: spine bone density 1.121 → 1.102 g/cm² vs 1.180 → 1.189 on placebo.
- 23
Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer (ATAC sub-protocol) ↗
Human study
Original abstract reviewed.
Detail: Anastrozole levels were 27% lower when taken with tamoxifen.
- 24
Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline ↗
Clinical practice guideline (US)
Original full text reviewed.
Detail: Statement 41: aromatase inhibitors, hCG or SERMs may be used for infertile men with low testosterone (Conditional; Grade C). Statement 42: no testosterone for men wanting fertility; adding other medicines to testosterone is too limited to recommend.
- 25
ARIMIDEX (anastrozole tablets): Product Monograph ↗
Product monograph (Canada)
Full label reviewed.
Detail: Indicated only for breast cancer in women after menopause; half-life about 50 hours; store at 15–30 °C.
- 26
Arimidex: Article 30 referral (harmonization of product information) ↗
Regulatory review (EU)
Original page reviewed.
Detail: Harmonized Arimidex product information across the EU for breast cancer in women after menopause.
- 27
Comparison of Effects of Chorionic Gonadotropin Alfa and Anastrozole on Sperm Retrieval Rate in Patients with Non-Mosaic Klinefelter Syndrome Following Microdissection Testicular Sperm Extraction ↗
Human report
Original full text reviewed.
Detail: 43 men with Klinefelter syndrome: sperm retrieved in 10 of 22 after anastrozole vs 4 of 21 after choriogonadotropin alfa (p = 0.065).
- 28
Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback ↗
Human study
Original abstract reviewed.
Detail: Research dose 10 mg/day for 7 days: estradiol fell, testosterone rose 53% in normal men; estradiol feeds back at both hypothalamus and pituitary.
- 29
Estrogen suppression in males: metabolic effects ↗
Human trial
Original abstract reviewed.
Detail: Young males: 0.5 mg and 1 mg daily each cut estradiol about 50% over 10 days; 10 weeks of 1 mg daily: estradiol −48%, testosterone +58%.
- 30
Testosterone and luteinizing hormone predict semen parameter improvement in infertile men treated with anastrozole ↗
Human report
Original abstract reviewed.
Detail: 90 men, median 3 mg a week: 41 improved sperm category, 11 worsened, 26 reached normal counts; estradiol did not predict response.
- 31
A comparison of anastrozole and testosterone versus placebo and testosterone for treatment of sexual dysfunction in men with epilepsy and hypogonadism ↗
Human trial
Original abstract reviewed.
Detail: 40 men with epilepsy on testosterone injections: sexual function normalized in 72.2% with anastrozole vs 47.4% with placebo, not significant.
- 32
Combination therapy with clomiphene citrate and anastrozole is a safe and effective alternative for hypoandrogenic subfertile men ↗
Human report
Original abstract reviewed.
Detail: 51 men on clomiphene with anastrozole added for estradiol above 50 pg/mL or a ratio below 10; 11 had side effects, including 2 with hematocrit above 54%.
- 33
Treatment of Estrogen Levels in the Management of Hypogonadism: An Anonymous Survey of ISSM Members ↗
Clinician survey
Original abstract reviewed.
Detail: 489 clinicians: 69.4% treat symptomatic high estradiol, 47.7% asymptomatic, 14.4% preventively; anastrozole most used; starting doses 1 mg weekly to 1 mg daily.
- 34
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer ↗
Human trial
Original abstract reviewed.
Detail: 114 men on bicalutamide, 48 weeks: breast growth 73% placebo, 51% anastrozole, 10% tamoxifen.
- 35
ESMO Pocket Guideline: Breast Cancer (2023) ↗
Clinical practice guideline (Europe)
Original full text reviewed.
Detail: In men with breast cancer, an aromatase inhibitor must be given with a GnRH agonist.
- 36
Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels ↗
Human trial
Original abstract reviewed.
Detail: Testosterone Trials: larger rises in estradiol as well as testosterone went with larger gains in sexual desire and activity.
- 37
The hormonal regulation of men's sexual desire, arousal, and penile erection: recommendations from the fifth international consultation on sexual medicine (ICSM 2024) ↗
Consensus recommendations
Original full text reviewed.
Detail: Suggests not using aromatase inhibitors or non-aromatizable androgens to treat low sexual desire.
- 38
High estrogen in men after injectable testosterone therapy: the low T experience ↗
Human report
Original abstract reviewed.
Detail: Records of a US men's clinic chain: 20.2% had estradiol at or above 42.6 pg/mL by immunoassay; not linked to low libido. Clinic authors.
- 39
Leflutrozole in male obesity-associated hypogonadotropic hypogonadism: Ph 2b double-blind randomised controlled trial ↗
Human trial
Original abstract reviewed.
Detail: Investigational leflutrozole in 271 men with obesity, 24 weeks: testosterone normalized, no sexual or body-composition benefit; spine bone density −1.2% to −2.1% vs +0.7%.
- 40
Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypotestosteronemia ↗
Human trial
Original abstract reviewed.
Detail: 42 men with obesity, letrozole 6 months: testosterone 8.6 → 21.5 nmol/L with no physical or psychological benefit.
- 41
EAU Guidelines on Sexual and Reproductive Health: Male Hypogonadism ↗
Clinical practice guideline (Europe)
Original full text reviewed.
Detail: SERMs and aromatase inhibitors are off-label with poor evidence; long-term use can reduce bone density; they need an intact hypothalamic-pituitary-testicular axis.
- 42
A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility ↗
Systematic review
Original abstract reviewed.
Detail: 8 studies of aromatase inhibitors for male infertility; only two were placebo-controlled randomized trials (testolactone and letrozole, not anastrozole); the authors call for larger placebo-controlled trials.
- 43
Canadian Urological Association guideline on testosterone deficiency in men: Evidence-based Q&A ↗
Clinical practice guideline (Canada)
Original full text reviewed.
Detail: Men wanting fertility should avoid testosterone alone; hCG, SERMs and aromatase inhibitors are off-label alternatives.
- 44
The British Society for Sexual Medicine Guidelines on Male Adult Testosterone Deficiency, with Statements for Practice ↗
Clinical practice guideline (UK)
Original full text reviewed.
Detail: Alternatives to testosterone for men wanting fertility include hCG, off-label SERMs and aromatase inhibitors.
- 45
EAU Guidelines on Sexual and Reproductive Health: Male Infertility ↗
Clinical practice guideline (Europe)
Original full text reviewed.
Detail: Do not routinely treat unexplained infertility with SERMs or aromatase inhibitors (weak).
- 46
Aromatase inhibitors for male infertility ↗
Human report
Original abstract reviewed.
Detail: Subfertile men with a low testosterone-to-estradiol ratio: ratio 7.2 → 18.1 on anastrozole; in 25 oligospermic men, sperm 5.5 → 15.6 million/mL; no comparison group.
- 47
Outcomes of anastrozole in oligozoospermic hypoandrogenic subfertile men ↗
Human report
Original abstract reviewed.
Detail: 86 men on 1 mg daily: hormones improved in 95.3%; semen improved in 18 of 21 oligozoospermic men, not in azoospermic men.
- 48
Efficacy and safety of letrozole or anastrozole in the treatment of male infertility with low testosterone-estradiol ratio: A meta-analysis and systematic review ↗
Meta-analysis
Original abstract reviewed.
Detail: 10 studies, 666 men: improvements from baseline but no advantage over SERMs or hCG; less effect on motility.
- 49
Pharmacological non-hormonal treatment options for male infertility: a systematic review and network meta-analysis ↗
Network meta-analysis
Original abstract reviewed.
Detail: 14 randomized trials, 1,342 men: insufficient evidence for routine use of clomiphene, tamoxifen or aromatase inhibitors.
- 50
Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole ↗
Human trial
Original abstract reviewed.
Detail: Tamoxifen, but not anastrozole, reduced bicalutamide-induced breast growth and pain, used to prevent or to treat.
- 51
Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial ↗
Human trial
Original abstract reviewed.
Detail: 80 boys with pubertal gynecomastia, 6 months: 38.5% vs 31.4% responded on placebo (not significant).
- 52
Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole ↗
Human report
Original abstract reviewed.
Detail: Case report of 2 men whose breast growth on TRT improved with anastrozole.
- 53
EAA clinical practice guidelines - gynecomastia evaluation and management ↗
Clinical practice guideline (Europe)
Original abstract reviewed.
Detail: Drug treatment (SERMs, aromatase inhibitors) of gynecomastia not justified in general; surgery for long-lasting breast growth.
- 54
Management of Male Breast Cancer: ASCO Guideline ↗
Clinical practice guideline (US)
Original abstract reviewed.
Detail: Tamoxifen first for men with hormone receptor-positive breast cancer; with a contraindication, a GnRH agonist or antagonist plus an aromatase inhibitor.
- 55
The Role of Aromatase Inhibitors in Male Prolactinoma ↗
Systematic review
Original abstract reviewed.
Detail: Aromatase inhibitors in dopamine-agonist-resistant male prolactinoma: 9 reported patients.
- 56
Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years ↗
Human trial
Original abstract reviewed.
Detail: 52 boys with growth hormone deficiency: authors report higher predicted adult height; the UK regulator's reading found no significant height benefit.
- 57
Management of non-medical androgen use: a position statement by the Society for Endocrinology ↗
Position statement (UK)
Original abstract reviewed.
Detail: Evidence for drugs, aromatase inhibitors included, to aid recovery after non-medical androgen use is limited and of low quality; most men recover within about 12 months.
- 58
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline ↗
Clinical practice guideline (US)
Original full text reviewed.
Detail: Routine monitoring covers testosterone, hematocrit and PSA; estradiol is not part of it.
- 59
A Review on Testosterone: Estradiol Ratio-Does It Matter, How Do You Measure It, and Can You Optimize It? ↗
Review
Original abstract reviewed.
Detail: A testosterone-to-estradiol ratio of 10–30 "seems" beneficial, but no optimal value is established.
- 60
Performance of direct estradiol immunoassays with human male serum samples ↗
Human study
Original abstract reviewed.
Detail: 101 men over 40: direct estradiol immunoassays read 6% to 74% higher than mass spectrometry.
- 61
Challenges to the measurement of estradiol: an Endocrine Society position statement ↗
Position statement (US)
Original abstract reviewed.
Detail: Routine methods cannot measure the low estradiol levels of men accurately.
- 62
PubChem Compound Summary: Estradiol (CID 5757), molecular weight ↗
Chemical database
Structured data reviewed.
Detail: Estradiol molecular weight 272.4 g/mol, so 1 pg/mL is about 3.67 pmol/L.
- 63
Rapid determination of anastrozole in plasma by gas chromatography with electron capture detection and its application to an oral pharmacokinetic study in healthy volunteers ↗
Human study
Original abstract reviewed.
Detail: 18 healthy men, single 1 mg dose: peak about 1.5 hours; half-life about 41–46 hours.
- 64
Compounding and the FDA: Questions and Answers ↗
Regulator guidance (US)
Original page reviewed.
Detail: Compounded drugs are not FDA-approved; FDA does not verify their safety, effectiveness or quality before marketing.
- 65
Anastrozole 1 mg film-coated tablets (Sun Pharmaceutical): Summary of Product Characteristics ↗
Product information (UK)
Full label reviewed.
Detail: UK generic 1 mg tablet; no special storage conditions.
- 66
Aromatase Inhibition Reduces Insulin Sensitivity in Healthy Men ↗
Human trial
Original abstract reviewed.
Detail: 17 healthy men, 6 weeks of 1 mg daily in a crossover trial: estradiol fell and insulin sensitivity fell.
- 67
Obesity and Baseline Estradiol Levels Are Independent Predictors for Initiation of Anastrozole in Hypogonadal Men on Clomiphene Citrate ↗
Human report
Original abstract reviewed.
Detail: 97 of 318 men on clomiphene had anastrozole added; obesity and baseline estradiol predicted it.
- 68
Letrozole and Infertility Among Males With Spermatogenic Failure: A Randomized Clinical Trial ↗
Human trial
Original abstract reviewed.
Detail: 296 infertile men, letrozole 2.5 mg daily for 3 months: lower libido in 18 of 147 vs 8 of 149.
- 69
Role of Aromatase Inhibitors in Managing Hypogonadism in Adult Males Related to Obesity and Aging: A Systematic Review and Meta-Analysis ↗
Meta-analysis
Original abstract reviewed.
Detail: Aromatase inhibitors instead of testosterone (3 randomized trials, 118 men): testosterone about 7 nmol/L higher at 3 months; spine bone density lower after 6 months.
- 70
Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels ↗
Human trial
Original abstract reviewed.
Detail: Same 37-man trial: no change in fasting lipids, inflammatory markers or insulin sensitivity over 12 weeks.
- 71
Testosterone vs. aromatase inhibitor in older men with low testosterone: effects on cardiometabolic parameters ↗
Human trial
Original abstract reviewed.
Detail: 29 older men, 12 months: neither testosterone gel nor anastrozole changed insulin resistance, CRP or lipids.
- 72
Cardiovascular Safety of Testosterone-Replacement Therapy ↗
Human trial
Original abstract reviewed.
Detail: TRAVERSE: heart attack, stroke or heart death 7.0% vs 7.3% (hazard ratio 0.96); testosterone gel, not anastrozole.
- 73
KYZATREX (testosterone undecanoate) capsules: prescribing information (TRAVERSE results) ↗
Product label (US)
Full label reviewed.
Detail: Class labeling with TRAVERSE results: atrial fibrillation 3.5% vs 2.4%, acute kidney injury 2.3% vs 1.5%, pulmonary embolism 0.9% vs 0.5%.
- 74
Testosterone Treatment and Fractures in Men with Hypogonadism ↗
Human trial
Original abstract reviewed.
Detail: TRAVERSE fracture substudy: clinical fractures 91 of 2,601 on testosterone vs 64 of 2,603 on placebo; hazard ratio 1.43.
- 75
Controlled Substances: Alphabetical Order (August 27, 2026) ↗
Controlled substance list (US)
Full list reviewed.
Detail: Anastrozole does not appear on the list of controlled substances.
- 76
openFDA Drug Shortages dataset (FDA Drug Shortages Database) ↗
Drug shortage data (US)
Structured data reviewed.
Detail: No entry for anastrozole.
- 77
Prescription Drug List (human use): anastrozole ↗
Prescription drug list (Canada)
Original page reviewed.
Detail: Anastrozole is on Canada's Prescription Drug List.
- 78
National Average Drug Acquisition Cost (NADAC): anastrozole 1 mg and Arimidex 1 mg tablets ↗
Drug pricing data (US)
Structured data reviewed.
Detail: Average pharmacy acquisition cost about $0.14 per generic 1 mg tablet and $52.86 per Arimidex tablet (not a retail price).
- 79
NHS Drug Tariff Part VIIIA, September 2026: anastrozole 1 mg tablets ↗
Reimbursement price (England and Wales)
Original table reviewed.
Detail: Anastrozole 1 mg tablets: 105 pence for 28 (Category M).
- 80
World Anti-Doping Code International Standard: Prohibited List 2026 ↗
Anti-doping list
Full list reviewed.
Detail: Aromatase inhibitors, including anastrozole, are prohibited at all times (S4.1; Specified Substances).
- 81
World Anti-Doping Code International Standard: Prohibited List 2027 (and explanatory note) ↗
Anti-doping list
Full list reviewed.
Detail: Keeps aromatase inhibitors and SERMs prohibited at all times.
- 82
Tamoxifen citrate tablets (Mylan): prescribing information ↗
Product label (US)
Full label reviewed.
Detail: Tamoxifen should not be coadministered with anastrozole.
- 83
Comparative effects of daily and weekly boron supplementation on plasma steroid hormones and proinflammatory cytokines ↗
Human study
Original abstract reviewed.
Detail: 8 healthy men, 10 mg boron a day for a week: plasma estradiol fell and free testosterone rose; no parallel control group; not men on TRT.
- 84
Crashed E2 on TRT and AI ↗
Community account
Public thread reviewed: opening post and 20 comments.
Detail: Felt well on TRT with estradiol 50; testosterone raised to 140 mg a week and 1 mg anastrozole weekly added; libido fell and estradiol tested below 5 after the second dose.
- 85
TRT levels and anastrozole ↗
Community account
Public thread reviewed: opening post and 19 comments.
Detail: After 100 lb of weight loss on TRT, prescribed 1 mg every 48 hours for an estradiol of 59.7 without symptoms; planned to ask about repeat labs.
- 86
Started TRT 1 Month already being prescribed Anastrozole, thoughts? ↗
Community account
Public thread reviewed: opening post and 28 comments.
Detail: Offered 0.5 mg one month into weekly injections for estradiol 40 pg/mL drawn at trough; switched to twice-weekly injections to retest.
- 87
Clinic completely tanked my estradiol with AI - How long until I feel alright again?? ↗
Community account
Public thread reviewed: opening post and 50 comments.
Detail: 1 mg weekly for an estradiol of 43; energy and libido fell; later estradiol below the measurable limit and hematocrit 60.
- 88
1mg anastrozole daily ↗
Community account
Public thread reviewed: opening post and 44 comments.
Detail: 1 mg daily with testosterone pellets for about a month; fatigue and anxiety; estradiol below the reportable range.
- 89
Anastrozole Side Effects ↗
Community account
Public thread reviewed: opening post and 50 comments.
Detail: 0.5 mg twice weekly for an estradiol of about 60; fatigue, poor sleep and loss of desire within about two weeks; stopped.
- 90
Estradiol levels and aromatase inhibitors with TRT ↗
Community account
Public thread reviewed: opening post and 28 comments.
Detail: 1 mg weekly from the start of TRT; stopped for joint pain, low mood and erection problems and felt better; prescriber asked him to restart at estradiol 66.
- 91
How to accurately dose Anastrozole? ↗
Community account
Public thread reviewed: opening post and 36 comments.
Detail: Bloating, nipple sensitivity and sexual problems eased on 0.5 mg a week; difficulty cutting unscored tablets.
- 92
Started to really feel TRT after a whole year after taking arimidex ↗
Community account
Public thread reviewed: opening post and 45 comments.
Detail: Estradiol 85 pg/mL after adding hCG; much deeper sleep within two days of anastrozole; no follow-up estradiol.
- 93
AI Advice needed please ↗
Community account
Public thread reviewed: opening post and 1 comments.
Detail: Itchy nipples at estradiol 55 pg/mL mostly settled on 0.5 mg every two to three days.
- 94
Cyp Test 200mg to 160mg and AI: Libido tanked ↗
Community account
Public thread reviewed: opening post and 46 comments.
Detail: Lowered testosterone and started an aromatase inhibitor at once; acne improved but libido and morning erections disappeared.
- 95
60mg trt worked better than 100mg trt with 0.5mg/week anastrozole ↗
Community account
Public thread reviewed: opening post and 33 comments.
Detail: Felt best on 60 mg a week; benefits faded after the dose rose to 100 mg with 0.5 mg anastrozole; cause unclear.
- 96
TRT 125mg/wk x 3 years — labs “good” but sleep + libido/ED worsening. AI helps a ton… for 1 night. How are people handling this? ↗
Community account
Public thread reviewed: opening post and 37 comments.
Detail: One 0.25 mg dose improved sleep and erections for one night, then problems returned.
- 97
Trying to Dial in Ultra-Low AI Dose to Prevent Estrogen Crash.Would Love Input ↗
Community account
Public thread reviewed: opening post and 15 comments.
Detail: Tried 0.03125 mg once a week after an earlier episode of low estradiol.
- 98
Struggling to find the right Arimidex dose on TRT, high aromatizer ↗
Community account
Public thread reviewed: opening post and 11 comments.
Detail: Low-estradiol symptoms on 0.25 mg three times weekly and high-estradiol symptoms on 0.125 mg twice weekly.
- 99
Arimidex and lipids ↗
Community account
Public thread reviewed: opening post and 20 comments.
Detail: Dose first written as 6.25 mg and 25 mg, corrected to 0.25 mg twice a week; worried about lipids.
- 100
E2 testing before ai ↗
Community account
Public thread reviewed: opening post and 5 comments.
Detail: Estradiol of 28 drawn two days after an anastrozole dose.
- 101
Anastrozole and AFib ↗
Community account
Public thread reviewed: opening post and 10 comments.
Detail: First episode of atrial fibrillation while on 0.5 mg twice weekly; cardiologist attributed it to stress.
- 102
Anastrozole induced PFS ↗
Community account
Public thread reviewed: opening post and 56 comments.
Detail: Persistent sexual symptoms attributed to one 0.25 mg dose taken after a booster supplement; later estradiol not low.
- 103
PFS replicated by anastrozole ↗
Community account
Public thread reviewed: opening post and 8 comments.
Detail: The same episode described in another community: numbness and sexual dysfunction after one 0.25 mg dose.
- 104
Anastrozole --Post finasteride style symptoms ↗
Community account
Public thread reviewed: opening post and 9 comments.
Detail: The same episode described again; estradiol reportedly never below 27.
- 105
Used arimidex with TRT and now it's been more than a month and my hair shedding doesn't stop ↗
Community account
Public thread reviewed: opening post and 10 comments.
Detail: Hair shedding after 15 days of 0.25 mg every two days; estradiol fell only from 85 to 65 pg/mL.
- 106
TRT Protocol Works Great, But Arimidex Crashed my HDL ↗
Community account
Public thread reviewed: opening post and 36 comments.
Detail: HDL 39.7 mg/dL on testosterone, hCG and anastrozole vs about 55–57 before treatment.
- 107
anastrozole absolutely wrecked me ↗
Community account
Public thread reviewed: opening post and 10 comments.
Detail: Hot flashes, flushing, palpitations and higher blood pressure after a first 0.5 mg dose; nipple sensitivity resolved.
- 108
3 months on clomiphene citrate and Anastrozole ↗
Community account
Public thread reviewed: opening post and 16 comments.
Detail: Clomiphene plus 1 mg anastrozole weekly instead of TRT; improvements alongside new weight training.
- 109
At what level of estradiol should I take my AI? ↗
Community account
Public thread reviewed: opening post and 11 comments.
Detail: Enclomiphene for fertility; stopped 1 mg twice weekly for joint pain; felt well on 0.25 mg twice weekly.
- 110
Raloxifene not stopping gyno on 460 mg Test E – started Arimidex but lump feels bigger ↗
Community account
Public thread reviewed: opening post and 16 comments.
Detail: Steroid cycle: added 0.25 mg to raloxifene for a tender lump, which felt slightly larger two days later.
- 111
Femara (letrozole) tablets: prescribing information ↗
Product label (US)
Full label reviewed.
Detail: Letrozole: approved only for breast cancer in women after menopause; half-life about 2 days; bone density warning.
- 112
Aromasin (exemestane) tablets: prescribing information ↗
Product label (US)
Full label reviewed.
Detail: Exemestane: steroidal aromatase inhibitor approved only for breast cancer in women after menopause; half-life about 24 hours; bone density warning.
- 113
Clomid (clomiphene citrate) 50 mg tablets: prescribing information ↗
Product label (US)
Full label reviewed.
Detail: Clomiphene is approved for ovulation problems in women.
- 114
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (categories list) ↗
Regulator list (US)
Full list reviewed.
Detail: Enclomiphene citrate is listed in Category 1 (under evaluation) for compounding; listing is not an approval.
- 115
EnCyzix (enclomifene): refusal of marketing authorisation ↗
Regulatory decision (EU)
Original page reviewed.
Detail: EU refused approval of enclomiphene: testosterone rose, but symptom benefit was not shown and clot risk was a concern.
No matching sources
Try a different term or show the full list.
Updates and corrections
Updated September 29, 2026. This version replaces the earlier anastrozole guide with a rewrite based on the current US, UK and Canadian labels, current guidelines and the original trials. It adds a protocol table with each schedule's source, the one published on-TRT clinic schedule, the guideline disagreement over using aromatase inhibitors on TRT, the evidence on bone, fertility and breast growth, storage rules, what happens when anastrozole stops, dated legal status and a comparison with related options. It corrects the earlier page on several points: the AUA guideline does give an anastrozole dose range, for use instead of testosterone rather than on TRT; ischemic heart events in women with existing heart disease were 17% vs 10%, not 4%; the Leder trial raised testosterone from 343 to 572 ng/dL (about 12 to 20 nmol/L), not 250 to 413; 0.5 mg and 1 mg lowered estradiol by a similar amount in young males, not proportionally; the clinician survey's first author is Butaney; aromatase inhibitors lower the estradiol-to-testosterone ratio in men by about 77%, not 50%; and anastrozole raises LH and FSH in men. Unsupported schedules (0.25 mg twice weekly, injection-day timing, as-needed dosing, co-implanted pellets) and unsupported monitoring intervals were removed. The date describes this revision, not a fresh check of every source.
Found an error or a relevant study we missed? Report a correction with the guide title, the specific passage and a supporting source if available. Please leave out personal health records. See our editorial policy for how we handle attribution, evidence limits and corrections.